Advertisement

Drugs

pp 1–17 | Cite as

The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events

  • Evan Elias
  • Laura E. TargownikEmail author
Therapy in Practice
  • 31 Downloads

Abstract

A substantial volume of literature exists linking proton pump inhibitor (PPI) use with a multitude of serious adverse events. There is uncertainty, however, over whether these associations are clinically important. Excessive concern about PPI-related adverse events may leave patients at risk of harm by leaving acid-related upper gastrointestinal disease untreated. Conversely, the risk of treatments may outweigh the benefits if any of the purported adverse events are directly caused by PPI use; this is of particular concern where indications for PPI use are not present. In this paper, we review the studies which have reported associations between adverse events and PPI use, discuss the proposed mechanisms of action, grade the confidence in whether these associations are truly causal, and provide advice regarding balancing the benefits of PPI use against their possible harms.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this manuscript

Conflicts of Interest

Evan Elias has no conflicts of interest to declare. Laura E. Targownik has no conflicts of interest to declare that directly relate to this manuscript.

References

  1. 1.
    IMS Institute for Healthcare Informatics. Declining medicine use and costs: For better or worse? A review of the use of medicines in the United States in 2012. Burlington, MA.Google Scholar
  2. 2.
    Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2015. AJHP. 2015;72(9):717–36.PubMedGoogle Scholar
  3. 3.
    Jaisser F, Beggah AT. The nongastric H+-K+-ATPases: molecular and functional properties. Am J Physiol. 1999;276(6):F812–24.PubMedGoogle Scholar
  4. 4.
    Novak I, Wang J, Henriksen KL, Haanes KA, Krabbe S, Nitschke R, et al. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem. 2011;286(1):280–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang J, Barbuskaite D, Tozzi M, Giannuzzo A, Sorensen CE, Novak I. Proton pump inhibitors inhibit pancreatic secretion: role of gastric and non-gastric H+/K+-ATPases. PLoS One. 2015;10(5):e0126432.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther. 1990;4(2):131–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.CrossRefPubMedGoogle Scholar
  9. 9.
    Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. BMJ. 1984;289(6447):717–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Del Piano M, Anderloni A, Balzarini M, Ballare M, Carmagnola S, Montino F, et al. The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the “gastric barrier effect” in patients chronically treated with PPI: a pilot study. J Clin Gastroenterol. 2012;46(Suppl):S18–26.CrossRefPubMedGoogle Scholar
  11. 11.
    Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope. 2008;118(4):599–604.CrossRefPubMedGoogle Scholar
  13. 13.
    Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11):e1006653.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Husebye E, Skar V, Hoverstad T, Melby K. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut. 1992;33(10):1331–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scand J Gastroenterol. 1996;31(9):875–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Castiglione F, Del Vecchio Blanco G, Rispo A, Petrelli G, Amalfi G, Cozzolino A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31(1):63–6.CrossRefPubMedGoogle Scholar
  17. 17.
    McLoughlin GA, Hede JE, Temple JG, Bradley J, Chapman DM, McFarland J. The role of IgA in the prevention of bacterial colonization of the jejunum in the vagotomized subject. Br J Surg. 1978;65(6):435–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–208.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–84.CrossRefPubMedGoogle Scholar
  23. 23.
    De La Cochetiere MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Dore J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005;43(11):5588–92.CrossRefGoogle Scholar
  24. 24.
    Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883 e9–885 e9.Google Scholar
  25. 25.
    Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.CrossRefPubMedGoogle Scholar
  26. 26.
    Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784–91.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57).CrossRefPubMedGoogle Scholar
  29. 29.
    Hassing RJ, Verbon A, de Visser H, Hofman A, Stricker BH. Proton pump inhibitors and gastroenteritis. Eur J Epidemiol. 2016;31(10):1057–63.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. GMR. 2015;14(3):7490–501.CrossRefPubMedGoogle Scholar
  31. 31.
    Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Tergast TL, Wranke A, Laser H, Gerbel S, Manns MP, Cornberg M, et al. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int. 2018;38(9):1602–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993;88(10):1801–2.PubMedGoogle Scholar
  36. 36.
    Stoschus B, Dominguez-Munoz JE, Kalhori N, Sauerbruch T, Malfertheiner P. Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol. 1996;8(8):811–3.PubMedGoogle Scholar
  37. 37.
    Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36(1):12–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90(9):1401–6.PubMedGoogle Scholar
  39. 39.
    Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12(3):247–53.CrossRefPubMedGoogle Scholar
  40. 40.
    Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992;51(Suppl 1):82–92.CrossRefPubMedGoogle Scholar
  41. 41.
    Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion. 1992;51(Suppl 1):76–81.CrossRefPubMedGoogle Scholar
  42. 42.
    Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997;112(3):707–17.CrossRefPubMedGoogle Scholar
  43. 43.
    Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5(4):206–14.CrossRefPubMedGoogle Scholar
  44. 44.
    Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018–22.CrossRefPubMedGoogle Scholar
  45. 45.
    Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19(16):2560–8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706 e5–1719 e5.CrossRefGoogle Scholar
  48. 48.
    Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44(9):915–25.CrossRefPubMedGoogle Scholar
  49. 49.
    Kinoshita Y, Tojo M, Yano T, Kitajima N, Itoh T, Nishiyama K, et al. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. Gastrointest Endosc. 1993;39(2):161–3.CrossRefPubMedGoogle Scholar
  50. 50.
    Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol. 1998;22(3):293–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32(9):1124–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Pascua MF, Kedia P, Weiner MG, Holmes J, Ellenberg J, Lewis JD. Microscopic colitis and medication use. Clin Med Insights Gastroenterol. 2010;2010(3):11–9.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E, et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013;19(2):411–7.PubMedGoogle Scholar
  54. 54.
    Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110(5):749–59.CrossRefPubMedGoogle Scholar
  55. 55.
    Bonderup OK, Fenger-Gron M, Wigh T, Pedersen L, Nielsen GL. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014;20(10):1702–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):1004–13.CrossRefPubMedGoogle Scholar
  57. 57.
    Andersen T, Andersen JR, Tvede M, Franzmann MB. Collagenous colitis: are bacterial cytotoxins responsible? Am J Gastroenterol. 1993;88(3):375–7.PubMedGoogle Scholar
  58. 58.
    Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut microbes. 2017;8(4):351–8.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Crowson MS, Shull GE. Isolation and characterization of a cDNA encoding the putative distal colon H+, K(+)-ATPase. Similarity of deduced amino acid sequence to gastric H+, K(+)-ATPase and Na+, K(+)-ATPase and mRNA expression in distal colon, kidney, and uterus. J Biol Chem. 1992;267(19):13740–8.PubMedGoogle Scholar
  60. 60.
    Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu Rev Physiol. 2016;78:481–504.CrossRefPubMedGoogle Scholar
  62. 62.
    El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113(3):755–60.CrossRefPubMedGoogle Scholar
  63. 63.
    Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.CrossRefPubMedGoogle Scholar
  66. 66.
    Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari IH, Sopjani M, Thaci K, et al. Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow up of 12 months. Open Access Maced. J Med Sci. 2018;6(3):442–6.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821 e1–829 e1.CrossRefGoogle Scholar
  68. 68.
    Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–4.CrossRefPubMedGoogle Scholar
  69. 69.
    Golubov J, Flanagan P, Adams P. Inhibition of iron absorption by omeprazole in rat model. Dig Dis Sci. 1991;36(4):405–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger–Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.CrossRefPubMedGoogle Scholar
  72. 72.
    Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.CrossRefPubMedGoogle Scholar
  74. 74.
    William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016;5(2):152–7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case–control study. PLoS Med. 2014;11(9):e1001736.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Sharara AI, Chalhoub JM, Hammoud N, Harb AH, Sarkis FS, Hamadeh G. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol. 2016;14(2):317–21.CrossRefPubMedGoogle Scholar
  77. 77.
    Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13.CrossRefPubMedGoogle Scholar
  78. 78.
    Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.CrossRefPubMedGoogle Scholar
  79. 79.
    Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O’Brien KO, Proctor DD, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.CrossRefPubMedGoogle Scholar
  82. 82.
    Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.CrossRefPubMedGoogle Scholar
  83. 83.
    Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.CrossRefPubMedGoogle Scholar
  84. 84.
    Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.CrossRefPubMedGoogle Scholar
  86. 86.
    Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101.CrossRefPubMedGoogle Scholar
  88. 88.
    Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62(6):473–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Colmenares EW, Pappas AL. Proton pump inhibitors: risk for myopathy? Ann Pharmacother. 2017;51(1):66–71.CrossRefPubMedGoogle Scholar
  90. 90.
    Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.CrossRefPubMedGoogle Scholar
  91. 91.
    Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One. 2017;12(2):e0171006.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971 e4–979 e4.CrossRefGoogle Scholar
  93. 93.
    Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112(12):1802–8.CrossRefPubMedGoogle Scholar
  94. 94.
    Wod M, Hallas J, Andersen K, Garcia Rodriguez LA, Christensen K, Gaist D. Lack of association between proton pump inhibitor use and cognitive decline. Clin Gastroenterol Hepatol. 2018;16(5):681–9.CrossRefPubMedGoogle Scholar
  95. 95.
    Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr. 2016;28(7):1059–65.CrossRefPubMedGoogle Scholar
  96. 96.
    Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65(9):1969–74.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Badiola N, Alcalde V, Pujol A, Munter LM, Multhaup G, Lleo A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case–control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597–604.CrossRefPubMedGoogle Scholar
  100. 100.
    Coca SG, Perazella MA. Early steroid treatment for drug-induced acute interstitial nephritis. Nat Clin Pract Nephrol. 2008;4(6):298–9.CrossRefPubMedGoogle Scholar
  101. 101.
    Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Dev Ther. 2017;11:1291–9.CrossRefGoogle Scholar
  102. 102.
    Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017;62(10):2821–7.CrossRefPubMedGoogle Scholar
  103. 103.
    Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. JASN. 2016;27(10):3153–63.CrossRefPubMedGoogle Scholar
  104. 104.
    Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–94.CrossRefPubMedGoogle Scholar
  106. 106.
    Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87(4):820–7.CrossRefPubMedGoogle Scholar
  107. 107.
    Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.CrossRefPubMedGoogle Scholar
  108. 108.
    Eiselt J, Rajdl D, Racek J, Vostry M, Rulcova K, Wirth J. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study. Kidney Blood Pressure Res. 2014;39(1):50–7.CrossRefGoogle Scholar
  109. 109.
    Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. JASN. 2014;25(4):657–70.CrossRefPubMedGoogle Scholar
  110. 110.
    Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.CrossRefPubMedGoogle Scholar
  111. 111.
    Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos Biol Fate Chem. 2010;38(1):92–9.CrossRefPubMedGoogle Scholar
  112. 112.
    Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–60.CrossRefPubMedGoogle Scholar
  113. 113.
    Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–44.CrossRefPubMedGoogle Scholar
  114. 114.
    Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713–8.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
  116. 116.
    O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.CrossRefPubMedGoogle Scholar
  117. 117.
    Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474–82.CrossRefPubMedGoogle Scholar
  118. 118.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.CrossRefPubMedGoogle Scholar
  119. 119.
    Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129(9):1002–5.CrossRefPubMedGoogle Scholar
  120. 120.
    Shell WE, DeWood MA, Peter T, Mickle D, Prause JA, Forrester JS, et al. Comparison of clinical signs and hemodynamic state in the early hours of transmural myocardial infarction. Am Heart J. 1982;104(3):521–8.CrossRefPubMedGoogle Scholar
  121. 121.
    Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–84.CrossRefPubMedGoogle Scholar
  122. 122.
    Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):148 e1–5.CrossRefPubMedGoogle Scholar
  123. 123.
    Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2015;21(3):194–200.CrossRefPubMedGoogle Scholar
  124. 124.
    Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2015;16(1):33–9.CrossRefPubMedGoogle Scholar
  125. 125.
    Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257–63.CrossRefPubMedGoogle Scholar
  126. 126.
    Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/logic randomized clinical trial. JAMA Oncol. 2017;3(6):767–73.CrossRefPubMedGoogle Scholar
  127. 127.
    Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310(18):1137–40.CrossRefPubMedGoogle Scholar
  128. 128.
    Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893–9.CrossRefPubMedGoogle Scholar
  129. 129.
    Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca–Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671–5.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–66.CrossRefPubMedGoogle Scholar
  131. 131.
    Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26(3):341–6.CrossRefPubMedGoogle Scholar
  132. 132.
    Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90–7.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):319–24.CrossRefPubMedGoogle Scholar
  134. 134.
    Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther. 1996;34(1 Suppl):S81–5.PubMedGoogle Scholar
  135. 135.
    Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569–72.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med. 1991;115(7):540–5.CrossRefPubMedGoogle Scholar
  137. 137.
    Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1996;34(1 Suppl):S67–71.PubMedGoogle Scholar
  138. 138.
    Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29(1):35–50.CrossRefPubMedGoogle Scholar
  139. 139.
    Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674–85.CrossRefPubMedGoogle Scholar
  140. 140.
    Grasela TH Jr, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, Schultz RW, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615–7.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol. 2005;45(7):845–50.CrossRefPubMedGoogle Scholar
  142. 142.
    Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288–98.CrossRefPubMedGoogle Scholar
  143. 143.
    Bell JS, Strandberg TE, Teramura-Gronblad M, Laurila JV, Tilvis RS, Pitkala KH. Use of proton pump inhibitors and mortality among institutionalized older people. Arch Intern Med. 2010;170(17):1604–5.PubMedGoogle Scholar
  144. 144.
    Wilson N, Gnjidic D, March L, Sambrook P, Hilmer SN. Use of PPIs are not associated with mortality in institutionalized older people. Arch Intern Med. 2011;171(9):866 (author reply-7).CrossRefPubMedGoogle Scholar
  145. 145.
    Teramura-Gronblad M, Bell JS, Poysti MM, Strandberg TE, Laurila JV, Tilvis RS, et al. Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland. J Am Med Direct Assoc. 2012;13(5):488 e9–513 e9.CrossRefGoogle Scholar
  146. 146.
    Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518–23.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep. 2018;3(2):374–84.CrossRefPubMedGoogle Scholar
  148. 148.
    Pegoli MA, Dedigama M, Mangoni AA, Russell PT, Grzeskowiak LE, Thynne T. Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities. Ther Adv Drug Saf. 2017;8(4):137–9.CrossRefPubMedGoogle Scholar
  149. 149.
    Pello Lazaro AM, Cristobal C, Franco-Pelaez JA, Tarin N, Acena A, Carda R, et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PLoS One. 2017;12(1):e0169826.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228–34.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Section of Gastroenterology, Department of Internal Medicine, Rady School of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations